

Sumera Irie Ilyas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3692839/publications.pdf>

Version: 2024-02-01

14
papers

417
citations

1478505

6
h-index

1588992

8
g-index

15
all docs

15
docs citations

15
times ranked

142
citing authors

#	ARTICLE	IF	CITATIONS
1	Transplant oncology in locally advanced intrahepatic cholangiocarcinoma: One more step on a long road. American Journal of Transplantation, 2022, 22, 685-686.	4.7	2
2	Hepatology Highlights. Hepatology, 2022, 75, 241-242.	7.3	0
3	PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF- β 2 receptor I versus II. Cell Reports, 2022, 38, 110349.	6.4	15
4	Hepatology Highlights. Hepatology, 2022, 75, 775-776.	7.3	0
5	Drivers and breaks in the cholangiocarcinoma immune microenvironment. Hepatobiliary Surgery and Nutrition, 2022, 11, 320-323.	1.5	0
6	Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology, 2022, 75, 1604-1626.	7.3	97
7	Hepatology highlights. Hepatology, 2022, 75, 1071-1072.	7.3	0
8	Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma. Cancers, 2022, 14, 2120.	3.7	10
9	Hepatology highlights. Hepatology, 2022, 75, 1363-1364.	7.3	0
10	Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opinion on Investigational Drugs, 2021, 30, 429-438.	4.1	13
11	MEK Inhibition. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1153-1154.	4.5	0
12	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology, 2021, 5, 1228-1240.	3.0	2
13	Cholangiocarcinoma. Nature Reviews Disease Primers, 2021, 7, 65.	30.5	270
14	Cholangiocarcinoma: what are the most valuable therapeutic targets “ cancer-associated fibroblasts, immune cells, or beyond T cells?. Expert Opinion on Therapeutic Targets, 2021, 25, 835-845.	3.4	8